Drugs for Cardiomyopathy, Familial Hypertrophic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 84)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Spironolactone |
Approved |
Phase 4 |
|
1952-01-7, 52-01-7 |
5833 |
Synonyms:
ABBOLACTONE
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone a
Aldactone®|spiractin|spirotone
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alpharma brand OF spironolactone
Alter brand OF spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Azupharma brand OF spironolactone
Betapharm brand OF spironolactone
Cardel brand OF spironolactone
CAROSPIR
CT Arzneimittel brand OF spironolactone
CT, Spiro von
CT-Arzneimittel brand OF spironolactone
Deverol
Dexo brand OF spironolactone
DIATENSEC
Dira
Duraspiron
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
GX SPIRONOL
Hormosan brand OF spironolactone
Jenapharm brand OF spironolactone
Jenaspiron
Lacalmin
Lacdene
LARACTONE
Mayoly-spindler brand OF spironolactone
Melarcon
Merck dura brand OF spironolactone
Mundogen brand OF spironolactone
Nefurofan
Novo spiroton
Novopharm brand OF spironolactone
Novo-spiroton
NovoSpiroton
NSC-150399
Osyrol
Pfizer brand OF spironolactone
|
Pharmafrid brand OF spironolactone
Practon
Roche brand OF spironolactone
Sagisal
SC-9420
Searle brand OF spironolactone
Sincomen
SNL
Spiractin
Spiresis
SPIRETIC
Spiridon
SPIRNOLACTONE
Spiro l.u.t.
Spiro von CT
Spirobeta
Spiroctan
SPIROCTAN 100
SPIROCTAN 25
SPIROCTAN 50
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono isis
Spironocompren
Spirono-isis
SPIRONOLACTONE
Spironolactone [BAN:INN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
SPIROSPARE 100
SPIROSPARE 25
Spiro-Tablinen
SPIROTONE
Sprioderm
Supra-puren
Suracton
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
Von CT, spiro
Wörwag brand OF spironolactone
Xenalon
|
|
2 |
|
Ranolazine |
Approved, Investigational |
Phase 4 |
|
142387-99-3, 95635-55-5 |
56959 |
Synonyms:
(-)-Ranolazine
CVT-303
Dihydrochloride, ranolazine
HCL, Ranolazine
Hydrochloride, ranolazine
N-(2,6-DIMETHYLPHENYL)-2-[4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]PIPERAZIN-1-YL]ACETAMIDE
N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
Ranexa
Ranolazina
|
Ranolazine
Ranolazine 2HCL
Ranolazine dihydrochloride
Ranolazine HCL
Ranolazine hydrochloride
Renolazine
RS-43285
RS-43285-003
|
|
3 |
|
Ethanol |
Approved |
Phase 4 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
4 |
|
Metoprolol |
Approved, Investigational |
Phase 4 |
|
37350-58-6, 51384-51-1 |
4171 |
Synonyms:
(+/-)-metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
Beatrolol
Beloc
Beloc duriles
Beloc-duriles
BelocDuriles
Betaloc
Betaloc astra
Betaloc-astra
BetalocAstra
Betalok
CGP-2175
CGP-2175C
CGP-2175C|GP-2175E|H-93/26|Lopressor®|Toprol®
CR-XL, Metoprolol
DL-Metoprolol
GP-2175E
H-93/26
Lopresor
Lopresoretic
LOPRESSIDONE
Lopressor
Lopressor HCT
|
Meijoprolol
Metohexal
METOPROLOL
Metoprolol CR XL
Metoprolol CR-XL
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metroprolol
Preblok
Prelis
Presolol
Seloken
Selopral
Selo-Zok
Seroken
Spesicor
Spesikor
Succinate, metoprolol
Tartrate, metoprolol
Toprol
Toprol XL
ToprolXL
Toprol-XL
|
|
5 |
|
Verapamil |
Approved |
Phase 4 |
|
152-11-4, 52-53-9 |
2520 |
Synonyms:
Akilen
Anpec
ANSYR
Ansyr®|CP-165331 / CP-16533-1|Securon®
Apo-verap
Arpamyl
Arpamyl LP
BERKATENS
CALAN
CALAN SR
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor retard
Coraver
CORDILOX
CORDILOX I.V.
CORDILOX MR 240
Cordilox SR
Corpamil
COVERA
COVERA-HS
CP-165331
CP-16533-1
CP-165331 / CP-16533-1
CP-16533-1Calan
CP-165331Verapamil
D-365
D-365Iproveratril
delta-365
Dexverapamil
Dignover
Dilacoran
Dilacoran hta
Drosteakard
Durasoptin
Elthon
ETHIMIL MR 240
Falicard
Finoptin
Flamon
GEANGIN
HALF SECURON SR
Harteze
Hexasoptin
Hexasoptin retard
Hormitol
Hydrochloride, verapamil
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
ISOPTIN
Isoptin retard
ISOPTIN SR
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
Lekoptin
Lodixal
LU-20175
Magotiron
Manidon
Manidon retard
MANIDON SR
Novapamyl LP
Novo-veramil
|
NSC-272306NA
NSC-272366
NSC-657799
Nu-verap
Ormil
Praecicor
Quasar
RANVERA MR
Rapam
Robatelan
Sandoz brand OF verapamil
SECURON
SECURON IV
SECURON MID
SECURON SR
Tarka
UNIVER
Univex
Vasolan
Vasomil
Vasopten
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Vérapamil
Verapamil [Usan:Ban:Inn]
Verapamil acis
Verapamil al
Verapamil atid
Verapamil basics
Verapamil ebewe
VERAPAMIL HCL
Verapamil henning
Verapamil hydrochloride
Verapamil injection
Verapamil MSD
Verapamil NM
Verapamil NM pharma
Verapamil nordic
Verapamil PB
Verapamil riker
Verapamil sandoz brand
Verapamil SR
Verapamil verla
Verapamil-abz
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
VERAPRESS MR 240
Veraptin
Verasal
Vera-sanorania
Verasifar
Veratensin
VERA-TIL SR
Verdilac
VERELAN
VERELAN PM
Verelan SR
Verexamil
Veroptinstada
Verpamil
VERTAB SR 240
Vetrimil
Vortac
ZOLVERA
|
|
6 |
|
Bisoprolol |
Approved |
Phase 4 |
|
66722-44-9 |
2405 |
Synonyms:
(+-)-1-((a-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((Α-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
Bisoprolol
Bisoprolol fumarate
Bisoprolol fumarate (1:1) salt, (+-)-isomer
Bisoprolol fumarate (2:1) salt, (+-)-isomer
Bisoprolol fumerate
Bisoprolol hemifumarate
Bisoprolol hydrochloride
Bisoprolol methanesulfonate salt
Bisoprolol, (-)-isomer
Bisoprolol, (+-)-isomer
Bisoprolol, fumarate (1:1) salt
Bisoprolol, fumarate (2:1) salt
Bisoprololum
Cardicor
CL-297939
|
Concor
Condyline
Condylox
CONGESCOR
Detensiel
Emconcor
Emcor
EMD-33512
EMD-33-512
Euradal
Fumarate, bisoprolol
Hydrochloride, bisoprolol
Isoten
Merck brand OF bisoprolol fumarate
Monocor
Soloc
Soprol
ZEBETA
ZIAC
|
|
7 |
|
Dobutamine |
Approved |
Phase 4 |
|
34368-04-2 |
36811 |
Synonyms:
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-b-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
Boehringer ingelheim brand OF dobutamine hydrochloride
COMPOUND 81929
COMPOUND-81929
DL-Dobutamine
Dobucor
Dobuject
Dobutamin
Dobutamin fresenius
Dobutamin hexal
Dobutamin ratiopharm
Dobutamin solvay
Dobutamina
Dobutamina [INN-Spanish]
Dobutamina inibsa
Dobutamina rovi
Dobutamine
Dobutamine (+)-isomer
Dobutamine [Usan:Ban:Inn]
Dobutamine [Usan]
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine hydrobromide
Dobutamine hydrochloride
dobutamine hydrochloride|Dobutrex®|Inotrex®
Dobutamine lactobionate
Dobutamine phosphate (1:1) salt, (-)-isomer
|
Dobutamine tartrate
Dobutamine tartrate (1:1), (R-(r*,r*))-isomer
Dobutamine tartrate (1:1), (S-(r*,r*))-isomer
Dobutamine, (-)-isomer
Dobutamine, phosphate (1:1) salt (+)-isomer
Dobutamin-ratiopharm
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
Eli lilly brand OF dobutamine hydrochloride
Fresenius brand OF dobutamine hydrochloride
Hexal brand OF dobutamine hydrochloride
Hydrobromide, dobutamine
Hydrochloride, dobutamine
Inibsa brand OF dobutamine hydrochloride
Inotrex
Irisfarma brand OF dobutamine hydrochloride
Juste brand OF dobutamine hydrochloride
Kendrick brand OF dobutamine hydrochloride
Lactobionate, dobutamine
Lilly 81929
Lilly brand OF dobutamine hydrochloride
Oxiken
Pisa brand OF dobutamine hydrochloride
Posiject
rac-Dobutamine
Racemic-dobutamine
Ratiopharm brand OF dobutamine hydrochloride
Rovi brand OF dobutamine hydrochloride
Solvay brand OF dobutamine hydrochloride
Tartrate, dobutamine
|
|
8 |
|
Adenosine |
Approved, Investigational |
Phase 4 |
|
58-61-7 |
60961 |
Synonyms:
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-METHYLOL-TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4S,5R)-2-(6-AMINO-9H-PURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-ribofuranose
6-Amino-9-b-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9-β-D-ribofuranosyl-9H-purine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-Î’-D-ribofuranosidoadenine
9-Î’-D-ribofuranosyl-9H-purin-6-amine
ADENIN RIBOSIDE
Adenine deoxyribonucleoside
|
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenocard
Adenocard®|Adenoscan®
Adenocor
ADENOGESIC
Adenoscan
Adenosin
ADENOSINA
ADENOSINE
ADÉNOSINE
ADENOSINUM
Adenyldeoxyriboside
Ade-rib
Ado
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
Boniton
Deoxyadenosine
Desoxyadenosine
Myocol
NSC-7652
Nucleocardyl
Sandesin
SR-96225
Î’-D-adenosine
|
|
9 |
|
Regadenoson |
Approved, Investigational |
Phase 4 |
|
313348-27-5 |
22451303 219024 |
Synonyms:
1-{6-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-2-yl}-N-methyl-1H-pyrazole-4-carboximidate
CVT-3146
CVT-3146|Lexiscan®|Rapiscan®
|
Lexiscan
REGADENOSON
Regadenoson anhydrous
|
|
10 |
|
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium |
Experimental |
Phase 4 |
|
461-06-3 |
|
Synonyms:
CARNITINE
CARNITINE CHLORIDE
|
|
|
11 |
|
Hormones |
|
Phase 4 |
|
|
|
12 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
13 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
14 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
15 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
16 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
17 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
18 |
|
Adrenergic beta-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
19 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
21 |
|
Sympatholytics |
|
Phase 4 |
|
|
|
22 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
23 |
|
Cardiotonic Agents |
|
Phase 4 |
|
|
|
24 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
25 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
26 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
27 |
|
Protective Agents |
|
Phase 4 |
|
|
|
28 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
29 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
30 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
31 |
|
Analgesics |
|
Phase 4 |
|
|
|
32 |
|
Valsartan |
Approved, Investigational |
Phase 2, Phase 3 |
|
137862-53-4 |
60846 |
Synonyms:
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
CGP-48933
CGP-48933|Diovan®|Prexxartan® (oral solution)
Diovan
EXFORGE
Kalpress
Miten
N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
|
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
PREXXARTAN
Provas
Tareg
VAL489
Vals
VALSARTAN
|
|
33 |
|
Angiotensin II |
Approved, Investigational |
Phase 2, Phase 3 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
34 |
|
Amiodarone |
Approved, Investigational |
Phase 3 |
|
1951-25-3 |
2157 |
Synonyms:
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
2-N-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
Alphapharm brand OF amiodarone hydrochloride
Aminodarone
Amio-Aqueous IV
Amiobeta
Amiodarex
Amiodarona
Amiodarona [INN-Spanish]
AMIODARONE
Amiodarone base
Amiodarone HCL
Amiodarone hydrochloride
amiodarone hydrochloride|Cordarone®
Amiodarons
Amiodaronum
Amiodaronum [INN-Latin]
Amiohexal
Aratac
Armstrong brand OF amiodarone hydrochloride
Arycor
ASTA medica brand OF amiodarone hydrochloride
Berenguer infale brand OF amiodarone hydrochloride
Betapharm brand OF amiodarone hydrochloride
|
Braxan
Corbionax
Cordarex
Cordarone
Cordarone Intravenous
g Gam brand OF amiodarone hydrochloride
Hexal brand OF amiodarone hydrochloride
Hydrochloride, amiodarone
Kordaron
L-3428
Labaz
Leurquin brand OF amiodarone hydrochloride
Ortacrone
PACERONE
Pharma investi brand OF amiodarone hydrochloride
pms-Amiodarone
Rytmarone
Sanofi winthrop brand OF amiodarone hydrochloride
SKF 33134 a
SKF 33134-a
SKF-33134A
Tachydaron
Trangorex
Wyeth brand OF amiodarone hydrochloride
|
|
35 |
|
Diltiazem |
Approved, Investigational |
Phase 2, Phase 3 |
|
42399-41-7 |
39186 |
Synonyms:
(+)-cis-5-[2-(Dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(+)-cis-5-[2-(Dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetic acid ester
(+)-CIS-DILTIAZEM
(+)-cis-diltiazem|Cardizem®|CRD-401|D-(cis)-diltiazem|Dilacor-XR®|RG-83606
(2S,3S)-5-(2-(Dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-(2-(Dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetic acid
(2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
Acalix
Acetate (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Adizem
Aldizem
Altiazem
Anginyl
Angizem
Anoheal
Apo-Diltiaz
Biovail brand OF diltiazem hydrochloride
Britiazim
Bruzem
Calcicard
Cardil
Cardizem
Cardizem CD
Cardizem SR
Cardizen LA
Cartia XT
Citizem
Cormax
CRD 401
CRD-401
D-(CIS)-DILTIAZEM
D-cis-Diltiazem
Deltazen
|
Dilacor
Dilacor XR
DILACOR-XR
Diladel
Dilcontin
Dilpral
Dilren
Dilrene
Dilta-Hexal
DILT-CD
Diltia
DILTIAZEM
Diltiazem hydrochloride
Diltiazem malate
Diltiazemum
Dilticard
DILTZAC
Dilzem
Dilzen
Endrydil
Herbesser
Incoril AP
Masdil
Novo-Diltazem
Nu-Diltiaz
RG-83606
Surazem
Syn-Diltiazem
TIAMATE
Tiazac
Tiazac Tildiem
Tiazac XC
Viazem
Watson pharmaceuticals brand OF diltazem
|
|
36 |
|
Atorvastatin |
Approved |
Phase 3 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
ATORVASTATIN
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
Atorvastatina
Atorvastatine
Atorvastatinum
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
|
Cardyl
Faboxim
Hipolixan
Hydrate, atorvastatin calcium
LCF872
Lipitor
Lipitor®
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
Normalip
PREVENCOR
Sincol
Sortis
Sotis
TAHOR
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
Vastina
Xanator
Xarator
Xavator
ZARATOR
Zurinel
|
|
37 |
|
Empagliflozin |
Approved |
Phase 3 |
|
864070-44-0 |
73151030 11949646 |
Synonyms:
(1S)-1,5-ANHYDRO-1-(4-CHLORO-3-{4-[(3S)-TETRAHYDROFURAN-3-YLOXY]BENZYL}PHENYL)-D-GLUCITOL
(1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-((4-{((3S)-OXOLAN-3-YL)OXY}PHENYL)METHYL)PHENYL}-D-GLUCITOL
1-CHLORO-4-(GLUCOPYRANOS-1-YL)-2-(4-(TETRAHYDROFURAN-3-YLOXY)BENZYL)BENZENE
BI 10773
BI 10773|Jardiance®
BI10773
|
BI-10773
EMPAGLIFLOZIN
Empagliflozina
Empagliflozine
Empagliflozinum
JARDIANCE
|
|
38 |
|
Angiotensinogen |
|
Phase 2, Phase 3 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
39 |
|
Angiotensin Receptor Antagonists |
|
Phase 2, Phase 3 |
|
|
|
40 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Giapreza |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Sacubitril and valsartan sodium hydrate drug combination |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
44 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
45 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
46 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
47 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
48 |
|
Sodium-Glucose Transporter 2 Inhibitors |
|
Phase 3 |
|
|
|
49 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
50 |
|
Trimetazidine |
Approved, Investigational |
Phase 2 |
|
5011-34-7 |
21109 |
Synonyms:
1-[2,3,4-TRIMETHOXYBENZYL] PIPERAZINE DIHYDROCHLORIDE
40045
Alpharma brand OF trimetazidine dihydrochloride
Biopharma brand OF trimetazidine dihydrochloride
Centrophène
Danval brand OF trimetazidine dihydrochloride
Dihydrochloride, trimetazidine
Dilatan
Idaptan
|
Irex brand OF trimetazidine dihydrochloride
Trimetazidina
TRIMETAZIDINE
Trimetazidine dihydrochloride
TRIMETAZIDINE HCL
Trimétazidine irex
Vasartel
Vastarel
VASTAREL MR
|
|
Interventional clinical trials:
(show top 50)
(show all 174)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness. |
Unknown status |
NCT01904396 |
Phase 4 |
Carnitine |
2 |
Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial |
Unknown status |
NCT02948998 |
Phase 4 |
Spironolactone |
3 |
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy |
Completed |
NCT00879060 |
Phase 4 |
Spironolactone;Placebo |
4 |
Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation |
Completed |
NCT01721967 |
Phase 4 |
Ranolazine |
5 |
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy |
Recruiting |
NCT04133532 |
Phase 4 |
Metoprolol |
6 |
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy |
Recruiting |
NCT05569382 |
Phase 4 |
Verapamil;Bisoprolol;Placebo |
7 |
The Effects of Dobutamine on Postoperative Systolic Deformation and Diastolic Function in Patients With Hypertrophic Cardiomyopathy Operated for Aortic Valve Stenosis |
Suspended |
NCT01375335 |
Phase 4 |
Dobutamine |
8 |
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve |
Terminated |
NCT03249272 |
Phase 4 |
Regadenoson;Adenosine |
9 |
Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy |
Unknown status |
NCT00698074 |
Phase 3 |
|
10 |
Sinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC) |
Completed |
NCT00821353 |
Phase 3 |
Antiarrhythmic drugs |
11 |
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem |
Completed |
NCT00319982 |
Phase 2, Phase 3 |
Diltiazem;Placebo |
12 |
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy |
Completed |
NCT03470545 |
Phase 3 |
mavacamten;Placebo |
13 |
Clinical and Genetic Determinants of Disease Progression and Response to Lifestyle and Pharmacological Interventions in Patients With Hypertrophic Cardiomyopathy |
Completed |
NCT05366101 |
Phase 2, Phase 3 |
Sacubitril/Valsartan |
14 |
Statin Induced Regression of Cardiomyopathy Trial - SirCat |
Completed |
NCT00317967 |
Phase 3 |
Atorvastatin;Placebo |
15 |
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction |
Recruiting |
NCT05186818 |
Phase 3 |
CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg);Placebo to match CK-3773274 |
16 |
A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy |
Recruiting |
NCT05174416 |
Phase 3 |
Mavacamten;Placebo |
17 |
A Phase 3, Open-label, Single Arm, Clinical Study to Evaluate Efficacy, Safety and Tolerability of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy |
Recruiting |
NCT05414175 |
Phase 3 |
Mavacamten |
18 |
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) |
Active, not recruiting |
NCT03723655 |
Phase 2, Phase 3 |
mavacamten |
19 |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy |
Active, not recruiting |
NCT04349072 |
Phase 3 |
Mavacamten;Placebo |
20 |
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy |
Not yet recruiting |
NCT05582395 |
Phase 3 |
Mavacamten |
21 |
The Use of Empagliflozin in Patients With Hypertrophic Cardiomyopathy |
Not yet recruiting |
NCT05182658 |
Phase 3 |
Empagliflozin 10 MG;Placebo |
22 |
Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy |
Terminated |
NCT02291237 |
Phase 2, Phase 3 |
Eleclazine;Placebo |
23 |
A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure |
Withdrawn |
NCT02431221 |
Phase 3 |
Perhexiline;Placebo |
24 |
A Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic Cardiomyopathy |
Unknown status |
NCT01696370 |
Phase 2 |
Trimetazidine |
25 |
CArdiac Desynchronization In Obstructive Hypertrophic CardioMyopathy |
Unknown status |
NCT01332162 |
Phase 2 |
|
26 |
Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study |
Unknown status |
NCT00430833 |
Phase 2 |
candesartan |
27 |
Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy |
Completed |
NCT03832660 |
Phase 2 |
Sacubitril/Valsartan |
28 |
Hypertrophic Cardiomyopathy Symptom Release by BX1514M |
Completed |
NCT02590809 |
Phase 2 |
Treatment BX1514M;Placebo |
29 |
Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study) |
Completed |
NCT00500552 |
Phase 2 |
Perhexiline/Placebo |
30 |
Controlled Cross-Over Study of DDD Pacemaker Therapy in Symptomatic Children With Obstructive Hypertrophic Cardiomyopathy |
Completed |
NCT00001960 |
Phase 2 |
|
31 |
Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study |
Completed |
NCT00035386 |
Phase 2 |
|
32 |
Double-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic Function |
Completed |
NCT00011076 |
Phase 2 |
Pirfenidone |
33 |
A Randomized Prospective Comparison of DDD Chamber Pacing and Percutaneous Transluminal Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Associated With Severe Drug-Refractory Symptoms |
Completed |
NCT00001894 |
Phase 2 |
|
34 |
A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy |
Completed |
NCT03953989 |
Phase 2 |
Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die |
35 |
INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan. |
Completed |
NCT01447654 |
Phase 2 |
Losartan;Placebo |
36 |
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction |
Completed |
NCT02842242 |
Phase 2 |
MYK-461 |
37 |
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy |
Completed |
NCT01150461 |
Phase 2 |
losartan;placebo |
38 |
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction |
Completed |
NCT03442764 |
Phase 2 |
mavacamten;Placebo |
39 |
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM |
Completed |
NCT01912534 |
Phase 2 |
Valsartan;Placebo |
40 |
Study of Myocardial Perfusion by MRI |
Completed |
NCT00001631 |
Phase 2 |
|
41 |
The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy. |
Completed |
NCT03532802 |
Phase 2 |
Metoprolol Succinate;Placebo oral capsule |
42 |
A Randomised, Double-blind, Placebo-controlled, Phase 2 Evaluation of the Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy |
Recruiting |
NCT04706429 |
Phase 2 |
Trientine;Placebo |
43 |
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy |
Recruiting |
NCT04826185 |
Phase 2 |
IMB-1018972;Placebo |
44 |
Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM) |
Recruiting |
NCT04426578 |
Phase 2 |
Perhexiline |
45 |
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy |
Active, not recruiting |
NCT04219826 |
Phase 2 |
CK-3773274 (5 - 15 mg);CK-3773274 (10 - 30 mg);Placebo for CK-3773274 |
46 |
A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM) |
Active, not recruiting |
NCT04164732 |
Phase 2 |
LCZ696;Placebo |
47 |
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER) |
Active, not recruiting |
NCT03496168 |
Phase 2 |
mavacamten |
48 |
An Open-Label Study of CK-3773274 for Patients With Symptomatic Hypertrophic Cardiomyopathy (HCM) |
Enrolling by invitation |
NCT04848506 |
Phase 2 |
CK-3773274 (5 - 20 mg) |
49 |
A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction |
Not yet recruiting |
NCT05556343 |
Phase 2 |
MYK-224 |
50 |
A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function |
Terminated |
NCT02862600 |
Phase 2 |
Perhexiline |
|